Archive · 23 Jul 2025
Dr. Reddy's Q1 Profit Drops 11% Sequentially, But Revenue Up
Imagine Dr. Reddy's is like a company that makes medicine.
They made less money in the last few months compared to the previous ones.
But they made more money than they did this time last year!
Although their expenses went up, they still made a lot of money overall.
They are also working with another company to develop new medicines and launched a new product in India.
Even with the profit drop, their stock price went up a little bit.
Dr. Reddy's Laboratories' net profit decreased 11% sequentially in Q1 FY26.
The company's revenue increased both sequentially and year-over-year in the quarter.
Operating expenses increased, contributing to the decline in net profit.
Dr. Reddy's expanded its partnership with Alvotech and launched a new product in India.
The company's stock closed up 0.65% on Wednesday.
- Who
- Dr. Reddy's Laboratories, a global pharmaceutical company.
- What
- Dr. Reddy's Laboratories reported its financial results for Q1 FY26.
- When
- The report covers the first quarter of fiscal year 2026.
- Where
- The company is headquartered in Hyderabad.
- Why
- The net profit declined due to increased operating expenses.
Positive Factors
Negative Factors
Financial Performance
Positive Factors
Revenue growth and expansion of partnerships signal potential.
Negative Factors
Declining profit margins suggest the need for caution.
- Net Profit (Q1 FY26)
- Rs 1,409.6 crore
- Net Profit (Q4 FY25)
- Rs 1,587.3 crore
- Net Profit (YoY)
- Up over 1%
- Revenue (Q1 FY26)
- Rs 8,545.2 crore
- Stock Close
- Rs 1,248.0, up 0.65%